Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.
Christophe Piketty, MD, PhD
Advertisement
Articles by Christophe Piketty, MD, PhD
Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome
5